Clinical implications of genetic polymorphisms on stomach cancer drug therapy

Pharmacogenomics J. 2007 Apr;7(2):76-80. doi: 10.1038/sj.tpj.6500405. Epub 2006 Jun 27.

Authors

G Toffoli¹, E Cecchin

Affiliation

¹ Experimental and Clinical Pharmacology, CRO-National Cancer Institute, Aviano, Italy. gtoffoli@cro.it

PMID: 16801937
DOI: 10.1038/sj.tpj.6500405

No abstract available

Publication types

Review

MeSH terms

Antineoplastic Agents / pharmacokinetics
Antineoplastic Agents / therapeutic use*
Biotransformation / genetics
Fluorouracil / therapeutic use
Gene Expression Regulation, Enzymologic
Gene Expression Regulation, Neoplastic
Genotype
Humans
Patient Selection*
Polymorphism, Single Nucleotide*
Stomach Neoplasms / drug therapy*
Stomach Neoplasms / enzymology
Stomach Neoplasms / genetics*
Treatment Outcome

Substances

Antineoplastic Agents
Fluorouracil